GenHenn Venture
VC Fund
Cranbury, United States
GenHenn Venture is a VC fund in Cranbury focused on Health Care and Medical. GenHenn Capital is a single-family office that specializes in private equity and venture capital investments.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries GenHenn Venture invests in
Stages GenHenn Venture invests in
Countries GenHenn Venture invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Michael Hennessey
|
|||
Investment Focus
Industry
- Health Care 6 (60%)
- Medical 4 (40%)
- Biotechnology 4 (40%)
- Medical Device 3 (30%)
- Computer 1 (10%)
Stage
- Series A 5 (50%)
- Series B 3 (30%)
- Debt Financing 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Michael Hennessey
Executive
|
Executive | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Meduloc
|
Meduloc provides a platform of solutions for small and long bone fractures using internal fixation. The company develops solutions to address the clinical needs of patients and surgeons. | $4M / Series B / Aug 06, 2026 | |
DermaSensor
|
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer evaluation, given that the majority of Americans report never having been checked for skin cancer. The DermaSensor device is an affordable, handheld tool that uses machine learning and spectroscopy to objectively evaluate skin lesions forpotential cancer in seconds. | $16M / Series B / Oct 02, 2025 | |
Toragen
|
Toragen is focused on repurposing anti-viral drugs and developing novel immunotherapies to treat viral-associated cancers. | $12M / Debt Financing / Sep 30, 2025 | |
PreciseDx
|
PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes. Clinical teams can rely on PreciseDx for unmatched insights and actionable intelligence in determining the best treatment for each patient.Combining the power of artificial intelligence with its proprietary Morphology Feature Array™, PreciseDx creates disease-specific assays that deliver new levels of pathology information and insight on each patient's risk profile and likely outcomes to aid in treatment decision-making. | $11.2M / Series B / Jun 05, 2025 | |
Sonavex
|
Sonavex is committed to improving outcomes for surgical patients by using cutting-edge imaging technology to provide clinicians with visualization of critical data -- directly at the point of care. The company's technology offers a proprietary technology platform that utilizes ultrasound to detect blood clots after surgery, enabling cliniciansto measure critical intravascular flow metrics to detect post-operative clots directly at the point of care and improve outcomes. | $15M / Series A / Oct 24, 2024 | |
|
PreciseDx
|
PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes. Clinical teams can rely on PreciseDx for unmatched insights and actionable intelligence in determining the best treatment for each patient.Combining the power of artificial intelligence with its proprietary Morphology Feature Array™, PreciseDx creates disease-specific assays that deliver new levels of pathology information and insight on each patient's risk profile and likely outcomes to aid in treatment decision-making. | $20.7M / Series B / Aug 21, 2024 | |
Prana Thoracic
|
Houston-based medical device startup Prana Thoracic, Inc. is dedicated to developing solutions for early intervention in lung cancer. We are an experienced team of surgeons, engineers and entrepreneurs on a mission to tackle lung cancer; the #1 cancer killer in the US.The paradigm of screening, detection, and early intervention that has beendeployed in other major cancers has so far eluded lung cancer. As a result, only 16% of lung cancers are found at an early stage and the current 5-year survival rate is < 20%. Recent changes to lung cancer screening guidelines have illuminated a path to improving outcomes in lung cancer. However, these advances rely on excising suspicious nodules and providing sufficient tissue for definitive diagnosis. We believe this is the missing piece of the puzzle, and physicians need a new generation of surgical oncology tools for lung cancer.Prana Thoracic plans to revolutionize the early diagnosis and treatment of lung cancer by making it easier and less invasive to deal with the rapidly growing number of early suspicious lung nodules; ensuring that we do not miss the window of opportunity to intervene early. | $3M / Series A / Jun 18, 2024 | |
MEND
|
MEND is a life sciences company with a mission to help people heal and live their healthiest. The company is currently researching and developing targeted clinical nutrition and medical food interventions to enhance patient outcomes, from injury and surgery to aging and physical performance. MEND has been adopted by numerous hospitals, healthsystems, professional sports teams across all major leagues, and the elite forces of the US Military. The company is headquartered in New York City. | $16.5M / Series A / Jun 06, 2023 | |
Diligent Pharma
|
Diligent Pharma is a platform that streamlines the selection and qualification of clinical trial service providers. It simplifies and accelerates the process for identification, selection, and qualification of clinical trial service providers.Trial sponsors can access standardized Vendor Qualification Assessment (VQA) reports and Request forInformation (RFI) information from Diligent. As a result, they will require significantly less time and money to qualify a GCP vendor before beginning a clinical investigation. | $8.3M / Series A / May 15, 2023 | |
Xenocor
|
Xenocor offers a suite of leading edge, fog-free, single-use endoscopes for minimally invasive surgical procedures. This technology emerged from the Center for Medical Innovation at the University of Utah. The current product offerings are FDA cleared, CE Marked and patent protected. | $10M / Series A / Apr 18, 2023 |
Co-Investors
Eventide
2 deals together
FCA Venture Partners
2 deals together
LabCorp
2 deals together
Quest Diagnostics
2 deals together
Alumni Ventures
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does GenHenn Venture invest in?
GenHenn Venture invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact GenHenn Venture?
Public channels for GenHenn Venture include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at GenHenn Venture?
The team at GenHenn Venture includes Michael Hennessey (Executive). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
